Treatment of relapsed Wilms tumors: Lessons learned

Expert Review of Anticancer Therapy

Volumn 9, Issue 12, 2009, Pages 1807-1815

  Spreafico, Filippo ^a   Jones, Kathy Pritchard ^b   Malogolowkin, Marcio H ^c   Bergeron, Christophe ^d   Hale, Juliet ^e   De Kraker, Jan ^f   Dallorso, Sandro ^g   Acha, Thomás ^h   De Camargo, Beatriz ⁱ   Dome, Jeffrey S ^j   Graf, Norbert ^k  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d CENTRE LÉON BÉRARD   (France)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f EMMA CHILDREN S HOSPITAL   (Netherlands)

^g G GASLINI INSTITUTE   (Italy)

^h HOSPITAL MATERNO INFANTIL   (Spain)

ⁱ IM IN JK) Inst Do C   (Brazil)

^j CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^k SAARLAND UNIVERSITY   (Germany)

more..

Author keywords

Chemotherapy; Pediatric renal tumor; Relapse; Wilms tumor

Indexed keywords

ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; OXALIPLATIN; PROTEIN P53; RETINOIC ACID; SOMATOMEDIN C RECEPTOR ANTIBODY; THIOTEPA; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; GENE TARGETING; HIGH RISK PATIENT; HUMAN; KIDNEY SURGERY; MAINTENANCE THERAPY; MOLECULAR BIOLOGY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROBLASTOMA; NEPHROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RECURRENCE RISK; RECURRENT CANCER; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; KIDNEY NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; WILMS TUMOR;

EID: 73349125771     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.159     Document Type: Review

References (60)

1. Green DM, Breslow NE, Beckwith JB et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. J. Clin. Oncol. 16, 237-245 (1998).
2. de Kraker J, Graf N, van Tinteren H et al. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet 364, 1229-1235 (2004).
3. Tournade MF, Com-Nougué C, de Kraker J et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J. Clin. Oncol. 19, 488-500 (2001).
4. Neville HL, Ritchey ML. Wilms' tumor. Overview of the National Wilms' Tumor Study Group results. Urol. Clin. North Am. 27, 435-442 (2000).
5. Graf N, Tournade MF, de Kraker J. The role of preoperative chemotherapy in the management of Wilms's tumor. Urol. Clin. North Am. 27, 443-454 (2000). Provides a thorough overview on International Society of Pediatric Oncology trials and studies.
6. Green DM. The treatment of stages I-IV favourable histology Wilms' tumor. J. Clin. Oncol. 22, 1366-1372 (2004). Good overview on favorable histology Wilms tumor (WT) treated within National Wilms Tumor Studies.
7. Mitchell C, Pritchard-Jones K, Shannon R et al. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. Eur. J. Cancer 42, 2554-2262 (2006).
8. Kalapurakal JA, Dome JS, Pearlman EJ et al. Management of Wilms' tumour: current practice and future goals. Lancet Oncol. 5, 37 (2004).
9. Miser JS, Tournade MF. The management of relapsed Wilms tumor. Hematol. Oncol. Clin. North Am. 9, 1287-1302 (1995).
10. Garaventa A, Hartmann O, Bernard JL et al. Autologous bone marrow transplantation for pediatric Wilms' tumour: the experience of the European Bone Marrow Transplantation Solid Tumour Registry. Med. Pediatr. Oncol. 22, 11-14 (1994).
11. Dome JS, Liu T, Krasin M et al. Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital. J. Ped. Hematol. Oncol. 24, 192-198 (2002). Overview analyzing the improvement on recurrent therapy over time.
12. Grundy P, Breslow N, Green DM et al. Prognostic factors for children with recurrent Wilms' tumor: results from the second and third National Wilms' Tumor Study. J. Clin. Oncol. 5, 638-647 (1989). Excellent original paper on prognostic factors analysis.
13. van den Heuvel-Eibrink MM, Graf N, Pein F et al. Intracranial relapse in Wilms tumor patients. Pediatr. Blood Cancer 43, 737-741 (2004).
14. Lowis SP, Foot A, Gerrard MP et al. Central nervous system metastasis in Wilms tumor: a review of three consecutive United Kingdom trials. Cancer 83, 2023-2029 (1998).
15. Spreafico F, Pritchard-Jones K, Bergeron C, de Kraker J, Dallorso S, Graf N. Value and difficulties of a common European strategy for recurrent Wilms' tumor. Expert Rev. Anticancer Ther. 9(6), 693-696 (2009).
16. Tournade MF, Lemerle J, Brunat-Mentigny M et al. Ifosfamide is an active drug in Wilms' tumor: a Phase II study conducted by the French Society of Pediatric Oncology. J. Clin. Oncol. 6, 793-796 (1988).
17. Pein F, Pinkerton R, Tournade MF et al. Etoposide in relapsed Wilms' tumor: a Phase II study by the French Society of Pediatric Oncology. J. Clin. Oncol. 11, 1478-1481 (1993).
18. De Camargo B, Melarango R, Saba e Silva N et al. Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: experience of the Brazilian Wilms' Tumor Study Group. Med. Ped. Oncol. 22, 258-260 (1994).
19. Pein F, Tournade MF, Zucker JM et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor - a Phase II study by the French Society of Pediatric Oncology. J. Clin. Oncol. 12, 931-936 (1994).
20. Pinkerton CR, Groot-Loonen JJ, Morris-Jones PH, Pritchard J. Response rates in relapsed Wilms' tumor. A need for new effective agents. Cancer 67, 567-571 (1991).
21. Metzger ML, Stewart CF, Freeman BB 3rd et al. Topotecan is active against Wilms' tumor: results of a multi-institutional Phase II study. J. Clin. Oncol. 21, 3130-3136 (2007).
22. Pein F, Michon J, Valteau-Couanet D et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. J. Clin. Oncol. 16, 3295-3301 (1998) . Original experience exploring the use of high-dose chemotherapy in recurrent WT.
23. Kremens B, Gruhn B, Klingebiel T et al. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant. 30, 893-898 (2002).
24. Abu-Ghosh AM, Krailo MD, Goldman SC et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer group report. Ann. Oncol. 13, 460-469 (2002).
25. Malogolowkin M, Cotton CA, Green DM et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Ped. Blood Cancer 50, 236-241 (2008). Provides the largest therapeutic experience on high-risk recurrent WT.
26. Spreafico F, Bisogno G, Collini P et al. Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem-cell support: experience by the Italian Association of Pediatric Hematology and Oncology. Ped. Blood Cancer 51, 23-28 (2008).
27. Green DM, Cotton CA, Malogolowkin M et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr. Blood Cancer 48, 493-499 (2007). Provides the largest experience on standard-risk recurrent WT.
28. Pein F, Rey A, de Kraker J et al. Multivariate analysis of adverse prognostic factors (APF) in children with recurrent (Rec) Wilms' tumor (WT) after initial treatment according to SIOP-6 or SIOP-9 strategies. Med. Pediatr. Oncol. 33, 170 (1999) (Abstract 111). Excellent original paper on prognostic factors analysis.
29. Vujanic GM, Sandstedt B, Harms D et al. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med. Pediatr. Oncol. 38, 79-82 (2002).
30. Reinhard H, Schmidt A, Furtwängler R et al. Outcome of relapses of nephroblastoma in patients registered in the SIOP/GPOH trials and studies. Oncol. Rep. 20, 463-467 (2008).
31. Hale J, Hobson R, Moroz V, Sartori P. Results of UK Children's Cancer and Leukemia Group (CCLG) protocol for relapsed Wilms tumor (UKWR): unified relapse strategy improves outcome. Proceeding of the 40th Meeting of International Society of Paediatric Oncology. 62 (2008) (Abstract O154).
32. Dome JS, Cotton CA, Pearlman EJ et al. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study. J. Clin. Oncol. 24, 2352-2358 (2006).
33. Daw NC, Gregornik D, Rodman J et al. Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumor. Eur. J. Cancer 45, 99-106 (2009).
34. Malogolowkin MH, Casak SJ, Feusner J et al. Carboplatin and etoposide alternating with ifosfamide and doxorubicin for the treatment of children with recurrent Wilms' tumors. Proceedings of ASCO. 13, 424 (1994) (Abstract 1453).
35. Campbell AD, Cohn SL, Reynolds M et al. Treatment of relapsed Wilms' Tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital. J. Clin. Oncol. 22, 2885-2890 (2004).
36. Tannous R, Giller R, Holmes E et al. Intensive therapy for high risk (HR) relapsed Wilm's tumor (WT). A CCG-4921/POG-9445 Study Report. Proceedings of ASCO. 19, 588a (2000) (Abstract 2315).
37. Nitschke R, Parkhurst J, Sullivan J et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group Phase II study. J. Pediatr. Hematol. Oncol. 20, 315-318 (1998).
38. Dome JS, Neale G, Hill DA et al. Anti-tumor activity of topotecan against Wilms tumor: translation of a xenograft model to Phase II study. Pediatr. Blood Cancer 45, 432-433 (2005).
39. Tubergen DG, Stewart CF, Pratt CB et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a Pediatric Oncology Group study. J. Pediatr. Hematol. Oncol. 18, 352-361 (1996).
40. Metzger ML, Stewart CF, Freeman BB 3rd et al. Topotecan is active against Wilms' tumor: results of a multi-institutional Phase II study. J. Clin. Oncol. 21, 3130-3136 (2007). Provides evidence about the activity of topotecan in WT.
41. Perlman EJ. Pediatric renal tumors: practical updates for the pathologists. Pediatr. Dev. Pathol. 8, 320-338 (2005). Provides a thorough overview of the new aspects concerning the current Childrens Oncology Group trials.
42. Green DM, Beckwith BJ, Breslow NE et al. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group. J. Clin. Oncol. 12, 2126-2131 (1994).
43. Italiano A, Sirvent N, Michiels JF et al. Tumour response to paclitaxel in an adult with relapsed nephroblastoma. Lancet Oncol. 6, 252-253 (2005).
44. Ramanathan RK, Rubin JT, Ohori NP, Belani CP. Dramatic response of adult Wilms' tumour to paclitaxel and cisplatin. Med. Pediatr. Oncol. 34, 296-298 (2000).
45. Spunt SL, Freeman BB 3rd, Billups CA et al. Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors. J. Clin. Oncol. 25, 2274 (2007).
46. McGregor LM, Spunt SL, Santana VL et al. Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors. Cancer 115, 655 (2009).
47. Ghanem MA, van Steenbrugge GJ, Sudaryo MK et al. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J. Clin. Pathol. 56, 107-113 (2003).
48. Benesch M, Wildenberg M, Sauseng W et al. Compassionate use of bevacizumab (Avastin® ) in children and young adults with refractory or recurrent solid tumors. Ann. Oncol. 19, 807-813 (2008).
49. Adamson PC, Matthay KK, O'Brein M, Reaman GH, Sato JK, Balis FM. A Phase 2 trial of all-trans-retinoic acid in combination with interferon-α2A in children with recurrent neuroblastoma or Wilms tumor: a Pediatric Oncology Branch, NCI and Children's Oncology Group study. Pediatr. Blood Cancer 49, 661-665 (2007).
50. Zirn B, Hartmann O, Samans B et al. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. Int. J. Cancer 118, 1954-1962 (2006).
51. Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, Gessler M. All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene 24, 5346-5251 (2005).
52. Witt O, Hämmerling S, Stockklausner C et al. 13-cis retinoic acid treatment of a patient with chemotherapy refractory nephroblastomatosis. J. Pediatr. Hematol. Oncol. 31, 296-299 (2009).
53. Green DM, Breslow NE, Ii Y et al. The role of surgical excision in the management of relapsed Wilms' tumor patients with pulmonary metastases: a report from the National Wilms' Tumor Study. J. Pediatr. Surg. 26, 728-733 (1991) .
54. Fuchs J, Szavay P, Luithle T, Furtwängler R, Graf N. Surgical implications for liver metastases in nephroblastoma - data from the SIOP/GPOH study. Surg. Oncol. 17, 33-40 (2008).
55. Bardeesy N, Beckwith JB, Pelletier J. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations. Cancer Res. 55, 215-219 (1995).
56. Bardeesy N, Falkoff D, Petruzzi MJ et al. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat. Genet. 7, 91-97 (1994).
57. Stock C, Ambros IM, Lion T et al. Genetic changes of two Wilms' tumors with anaplasia and a review of the literature suggesting a marker profile for therapy resistance. Cancer Genet. Cytogenet. 135, 128-138 (2002).
58. Natrajan R, Little SE, Sodha N et al. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. J. Pathol. 211, 52-59 (2007).
59. Huang CC, Gadd S, Breslow N et al. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children's Oncology Group. Clin. Cancer Res. 15, 1770-1778 (2009).
60. Grundy PE, Breslow NE, Li S et al. Loss of heterozygosity for chromosome 1p and 16q is an adverse prognostic factor in favourable histology Wilms tumor: a report from the National Wilms Tumor Study Group. J. Clin. Oncol. 23, 7312-7321 (2005). Provides new molecular markers of clinical utility for the therapy of favourable histology WT.